• Life sciences company focused on skin health
• Uses lysates of probiotic bacteria to increase skin integrity
• Efficacy shown in first human study of SkinBiotix cream
What SkinBioTherapeutics does
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance.
The company is currently targeting three main skincare sectors; cosmetics, infection control and eczema, with its most advanced research programme currently focused on using the SkinBiotix platform in cosmetics to manage sensitive skin.
• In mid-April, the company appointed Stuart John Ashman, the former sales and marketing director of wound care, casting and bandaging at FTSE 100-listed Smith & Nephew, to the board having previously designated him as the successor to CEO Dr Cath O'Neill in March
• Data from the first human study of the company’s SkinBiotix cream revealed that the product was well tolerated and efficacious in certain age groups and at certain time points, with the under 50s group seeing a statistically significant increase in skin hydration at day 15. There was also a small, but statistically significant decrease in transepidermal water loss at day 29 in the over 60s cohort
• In February, the company raised £1.5mln by selling shares to existing investor Seneca Partners, taking the investment manager’s holding in SkinBio to 20.9% from 14.6%
With Ashman scheduled to take over the CEO role, O’Neill going forward will be focusing on the scientific development of the SkinBiotix platform as well as the firm’s ongoing commercial discussions.
"Stuart's appointment as a director adds further commercial capability to the board. He has a considerable network within the medtech and life science industries and the experience and drive to take us forward on the next stage of the company's development," said Martin Hunt, the company’s non-executive chairman.
Ashman himself said that upon appointment his immediate focus would be for the company to “continue to support the clinical development of the technology whilst building on the ongoing commercial discussions.”
Regarding the results of the company’s first human trial, O’Neill says that the data will form “a launch pad” for talking to potential licensees for the SkinBiotix formula.
“Our potential [commercial] partners have said that provided the technology if safe…everything else can be sorted out by formulation.”
“We already knew it was safe because there have been no adverse effects reported…but to show efficacy on top of that is stellar”.
O’Neill added that following the data there was “a lot of scope” for the company to further optimise the formulation of the cream to make it more suitable for different age groups.
With shares trading at around 15.3p as of 1 May, SkinBioTherapeutics has a market cap of £20.49mln.